Literature DB >> 33334911

Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy.

Richard L Wahl1, Panithaya Chareonthaitawee2, Bonnie Clarke3, Alexander Drzezga4, Liza Lindenberg5, Arman Rahmim6, James Thackeray7, Gary A Ulaner8, Wolfgang Weber9, Katherine Zukotynski10, John Sunderland11.   

Abstract

The Society of Nuclear Medicine and Molecular Imaging created the Value Initiative in 2017 as a major component of its strategic plan to further demonstrate the value of molecular imaging and molecularly targeted radiopharmaceutical therapy to patients, physicians, payers, and funding agencies. The research and discovery domain, 1 of 5 under the Value Initiative, has a goal of advancing the research and development of diagnostic and therapeutic nuclear medicine. Research and discovery efforts and achievements are essential to ensure a bright future for NM and to translate science to practice. Given the remarkable progress in the field, leaders from the research and discovery domain and society councils identified 5 broad areas of opportunity with potential for substantive growth and clinical impact. This article discusses these 5 growth areas, identifying specific areas of particularly high importance for future study and development. As there was an understanding that goals should be both visionary yet achievable, this effort was called the Mars shot for nuclear medicine.
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  artificial intelligence; molecular imaging; neuroimaging; radiopharmaceutical therapy; theranostics

Mesh:

Substances:

Year:  2021        PMID: 33334911      PMCID: PMC9364879          DOI: 10.2967/jnumed.120.253450

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   11.082


  94 in total

1.  Parametric imaging: a promising approach for the evaluation of dynamic PET-18F-FDG studies - the DKFZ experience.

Authors:  Antonia Dimitrakopoulou-Strauss; Leyun Pan; Ludwig G Strauss
Journal:  Hell J Nucl Med       Date:  2010 Jan-Apr       Impact factor: 1.102

2.  Optimization of SPECT Measurement of Myocardial Blood Flow with Corrections for Attenuation, Motion, and Blood Binding Compared with PET.

Authors:  R Glenn Wells; Brian Marvin; Marlie Poirier; Jennifer Renaud; Robert A deKemp; Terrence D Ruddy
Journal:  J Nucl Med       Date:  2017-06-13       Impact factor: 10.057

3.  177Lu-Dotatate for Midgut Neuroendocrine Tumors

Authors:  Jonathan Strosberg; Eric Krenning
Journal:  N Engl J Med       Date:  2017-04-06       Impact factor: 91.245

4.  89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.

Authors:  Gary A Ulaner; David M Hyman; Serge K Lyashchenko; Jason S Lewis; Jorge A Carrasquillo
Journal:  Clin Nucl Med       Date:  2017-12       Impact factor: 7.794

5.  Longitudinal noninvasive imaging of progesterone receptor as a predictive biomarker of tumor responsiveness to estrogen deprivation therapy.

Authors:  Szeman Ruby Chan; Amy M Fowler; Julie A Allen; Dong Zhou; Carmen S Dence; Terry L Sharp; Nicole M Fettig; Farrokh Dehdashti; John A Katzenellenbogen
Journal:  Clin Cancer Res       Date:  2014-12-17       Impact factor: 12.531

Review 6.  Amyloid-plaque imaging in early and differential diagnosis of dementia.

Authors:  Alexander Drzezga
Journal:  Ann Nucl Med       Date:  2010-02       Impact factor: 2.668

7.  An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy.

Authors:  Richard Tavaré; Helena Escuin-Ordinas; Stephen Mok; Melissa N McCracken; Kirstin A Zettlitz; Felix B Salazar; Owen N Witte; Antoni Ribas; Anna M Wu
Journal:  Cancer Res       Date:  2015-11-16       Impact factor: 12.701

Review 8.  Improving dementia care: the role of screening and detection of cognitive impairment.

Authors:  Soo Borson; Lori Frank; Peter J Bayley; Malaz Boustani; Marge Dean; Pei-Jung Lin; J Riley McCarten; John C Morris; David P Salmon; Frederick A Schmitt; Richard G Stefanacci; Marta S Mendiondo; Susan Peschin; Eric J Hall; Howard Fillit; J Wesson Ashford
Journal:  Alzheimers Dement       Date:  2013-01-30       Impact factor: 21.566

9.  Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor.

Authors:  Johannes Toms; Jürgen Kogler; Simone Maschauer; Christoph Daniel; Christian Schmidkonz; Torsten Kuwert; Olaf Prante
Journal:  J Nucl Med       Date:  2020-04-24       Impact factor: 10.057

10.  Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers.

Authors:  M Syed; P Flechsig; J Liermann; P Windisch; F Staudinger; S Akbaba; S A Koerber; C Freudlsperger; P K Plinkert; J Debus; F Giesel; U Haberkorn; S Adeberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-05-23       Impact factor: 9.236

View more
  3 in total

Review 1.  Visualizing the dynamics of tuberculosis pathology using molecular imaging.

Authors:  Alvaro A Ordonez; Elizabeth W Tucker; Carolyn J Anderson; Claire L Carter; Shashank Ganatra; Deepak Kaushal; Igor Kramnik; Philana L Lin; Cressida A Madigan; Susana Mendez; Jianghong Rao; Rada M Savic; David M Tobin; Gerhard Walzl; Robert J Wilkinson; Karen A Lacourciere; Laura E Via; Sanjay K Jain
Journal:  J Clin Invest       Date:  2021-03-01       Impact factor: 14.808

Review 2.  Towards an era of precise diagnosis and treatment: Role of novel molecular modification-based imaging and therapy for dedifferentiated thyroid cancer.

Authors:  Jing Li; Yingjie Zhang; Fenghao Sun; Ligang Xing; Xiaorong Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

Review 3.  Next-Generation Molecular Imaging of Thyroid Cancer.

Authors:  Yuchen Jin; Beibei Liu; Muhsin H Younis; Gang Huang; Jianjun Liu; Weibo Cai; Weijun Wei
Journal:  Cancers (Basel)       Date:  2021-06-25       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.